Print Friendly, PDF & Email


SET, Phosphatase 2A Inhibitor I2PP2A


Catalogue number: X2378B

Synonyms
Template-activating factor I, TAF-I, HLA-DR-associated protein II, PHAPII, Inhibitor of granzyme A-activated DNase, IGAAD2PP2A; IGAAD; I2PP2A; PHAPII; TAF-IBETA

IsotypeIgG
Product Type Blocking Peptide
Units50 µg
HostRabbit
Species reactivity Human
Application Western Blot
Product Form
Unconjugated Affinity Purified

Background
Human SET was originally identified as part of the SET-CAN fusion gene produced by a somatic translocation event in a patient with acute undifferentiated leukemia. In developing kidney, SET is highly expressed in the zone of nephron morphogenesis. SET has been shown to be a potent and specific inhibitor of protein phosphatase 2A, a family of major serine/threonine phosphatases involved in regulating cell proliferation and differentiation. SET is also involved in the regulation of renal cell proliferation and tumorigenesis. SET mRNA expression is markedly reduced in cells rendered quiescent by serum starvation, contact inhibition, or differentiation. SET protein expression is also much greater in developing rat and human kidney than in fully differentiated, mature kidney. High levels of SET mRNA and SET protein expression arefound in Wilms' tumor, but not in renal cell carcinoma, adult polycystic kidney disease or in transitional cell carcinoma.

Positive Control
Widely expressed. Low levels in quiescent cells during serum starvation, contact inhibition or differentiation. Highly expressed in Wilms' tumor.

Immunogen
peptide

Concentration
See vial for concentration

Formulation
Provided as solution in phosphate buffered saline with 0.08% sodium azide

Functional Analysis
Western Blotting

Applications
For use with SET polyclonal antibodies (Cat. No. X2088P & X2332P).

Storage
Product should be stored at -20ºC. Aliquot to avoid freeze/thaw cycles

Ship Conditions
Ship on gel ice, store at -20ºC immediately upon arrival

Product Stability
Products are stable for one year from purchase when stored properly

References
[1] von Lindern M., van Baal S., Wiegant J., Raap A., Hagemeijer A., Grosveld G.; Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3' half to different genes: characterization of the set gene.; Mol. Cell. Biol. 12:3346-3355(1992). [2] von Lindern M., van Baal S., Wiegant J., Raap A., Hagemeijer A., Grosveld G.; Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3' half to different genes: characterization of the set gene.; Mol. Cell. Biol. 12:3346-3355(1992). [3] Vaesen M., Barnikol-Watanabe S., Goetz H., Adil Awni L., Cole T., Zimmermann B., Kratzin H.D., Hilschmann N.; Purification and characterization of two putative HLA class II associated proteins: PHAPI and PHAPII.; Biol. Chem. Hoppe-Seyler 375:113-126(1994). [4] Nagata K., Kawase H., Handa H., Yano K., Yamasaki M., Ishimi Y., Okuda A., Kikuchi A., Matsumoto K.; Replication factor encoded by a putative oncogene, set, associated with myeloid leukemogenesis.; Proc. Natl. Acad. Sci. U.S.A. 92:4279-4283(1995). [5] Li M., Makkinje A., Damuni Z.; The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A.; J. Biol. Chem. 271:11059-11062(1996). [6] Tsujio I., Zaidi T., Xu J., Kotula L., Grundke-Iqbal I., Iqbal K.; Inhibitors of protein phosphatase-2A from human brain: structures, immunocytological localization and activities towards dephosphorylation of the Alzheimer type hyperphosphorylated Tau.; Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases. [7] The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Genome Res. 14:2121-2127(2004). [8] Adachi Y., Pavlaki G.N., Copeland T.D.; Identification and characterization of SET, a nuclear phosphoprotein encoded by the translocation break point in acute undifferentiated leukemia.; J. Biol. Chem. 269:2258-2262(1994). [9] Wang L.C., Chen Y.; A relative factor in human rectum carcinoma.; Submitted (APR-2007) to the EMBL/GenBank/DDBJ databases. [10] Carlson S.G., Eng E., Kim E.-G., Perlman E.J., Copeland T.D., Ballermann B.J.; Expression of SET, an inhibitor of protein phosphatase 2A, in renal development and Wilms' tumor.; J. Am. Soc. Nephrol. 9:1873-1880(1998). [11] Seo S.-B., McNamara P., Heo S., Turner A., Lane W.S., Chakravarti D.; Regulation of histone acetylation and transcription by INHAT, a human cellular complex containing the Set oncoprotein.; Cell 104:119-130(2001). [12] Minakuchi M., Kakazu N., Gorrin-Rivas M.J., Abe T., Copeland T.D., Ueda K., Adachi Y.; Identification and characterization of SEB, a novel protein that binds to the acute undifferentiated leukemia-associated protein SET.; Eur. J. Biochem. 268:1340-1351(2001). [13] Fan Z., Beresford P.J., Zhang D., Lieberman J.; HMG2 interacts with the nucleosome assembly protein SET and is a target of the cytotoxic T-lymphocyte protease granzyme A.; Mol. Cell. Biol. 22:2810-2820(2002). [14] Fan Z., Beresford P.J., Oh D.Y., Zhang D., Lieberman J.; Tumor suppressor NM23-H1 is a granzyme A-activated DNase during CTL-mediated apoptosis, and the nucleosome assembly protein SET is its inhibitor.; Cell 112:659-672(2003). [15] Fan Z., Beresford P.J., Oh D.Y., Zhang D., Lieberman J.; Cell 115:241-241(2003). [16] Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.; Cell 127:635-648(2006). [17] Sprung R., Chen Y., Xu Y., Ball H., Pei J., Cheng T., Kho Y., Xiao H., Xiao L., Grishin N.V., White M., Yang X.-J., Zhao Y.; Substrate and functional diversity of lysine acetylation revealed by a proteomics survey.; Mol. Cell 23:607-618(2006). [18] Molina H., Horn D.M., Tang N., Mathivanan S., Pandey A.; Global proteomic profiling of phosphopeptides using electron transfer dissociation tandem mass spectrometry.; Proc. Natl. Acad. Sci. U.S.A. 104:2199-2204(2007).

Caution
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals.

Safety Datasheet(s) for this product:

Sodium Azide
/wp-content/uploads/2018/07/Antibody-SDS-with-Sodium-AzideV2.pdf

SET, Phosphatase 2A Inhibitor I2PP2A

$119.00


Brand

Contact us

Exalpha Biologicals, Inc.
2 Shaker Road, Unit B101
Shirley, MA 01464
Phone: 978-425-1370
Email: info@exalpha.com

Newsletter







Member